Cyrus Biotechnology Announces Selection of CYR212 as Clinical Candidate for Chronic IgG-driven Autoimmune Disease Including Myasthenia Gravis and Immune Thrombocytopenia (Business Wire)
Article can be read via the following link: https://www.businesswire.com/news/home/20250109147839/en/Cyrus-Biotechnology-Announces-Selection-of-CYR212-as-Clinical-Candidate-for-Chronic-IgG-driven-Autoimmune-Disease-Including-Myasthenia-Gravis-and-Immune-Thrombocytopenia
Cyrus Biotechnology Spins out Levitate Bio, a Protein AI, Bioinformatics, and Rosetta Service Provider, to Bring Automated, Customized AI Solutions to Biopharma Drug Discovery
https://www.businesswire.com/news/home/20240611967134/en/Cyrus-Biotechnology-Spins-out-Levitate-Bio-a-Protein-AI-Bioinformatics-and-Rosetta-Service-Provider-to-Bring-Automated-Customized-AI-Solutions-to-Biopharma-Drug-Discovery
Cyrus Biotechnology Announces Potent in vivo Redosability of an Engineered IdeS Protease for IgG-driven Autoimmune Disease, Demonstrating No Anti-drug Antibodies (Business Wire)
Read article at the link below: https://www.businesswire.com/news/home/20241211633894/en/Cyrus-Biotechnology-Announces-Potent-in-vivo-Redosability-of-an-Engineered-IdeS-Protease-for-IgG-driven-Autoimmune-Disease-Demonstrating-No-Anti-drug-Antibodies
Cyrus Biotechnology to Present its Protein Engineering Capability, Immunogenicity Risk Mitigation, and Best-in-Class IgG Protease Candidate at Hit ID Summit (Business Wire)
Cyrus CSO and co-founder Yifan Song performed a presentation at the Hit ID Summit in Boston, speaking on a few topics including Cyrus’ hybrid AI/screening platform in risk mitigation of protein therapeutics, Cyrus’ IgG protease candidate, and the company’s overall protein engineering capabilities. Check out the article for a summary of the presentation here
Cyrus Biotechnology Congratulate Co-Founder David Baker on 2024 Nobel Prize in Chemistry (Business Wire)
Cyrus co-founder and Computational Biologist David Baker was recently awarded as a 2024 Nobel Laureate in Chemistry. Congratulations to David on receiving such a prestigious honor. Here is the link to the Business Wire article of the news: https://www.businesswire.com/news/home/20241010773571/en/Cyrus-Biotechnology-Congratulates-David-Baker-2024-Nobel-Laureate-in-Chemistry-and-Cyrus-Co-Founder
Cyrus Biotechnology to Present Its Novel IgG-degrading IdeS Enzyme Development Candidates for Autoimmune Indications at PepTalk Conference in San Diego
Director of Discovery Dr. Erik Procko recently performed a presentation on Cyrus’ novel IgG-degrading IdeS enzyme development candidates at PepTalk Conference San Diego on January 16th. The article can be found via the following link: https://www.businesswire.com/news/home/20240116136157/en/Cyrus-Biotechnology-to-Present-Its-Novel-IgG-degrading-IdeS-Enzyme-Development-Candidates-for-Autoimmune-Indications-at-PepTalk-Conference-in-San-Diego/
Cyrus Biotechnology Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article highlighting the exciting potential of decoy receptor drugs in fighting SARS-CoV-2, and other viral infections – (Science.com)
https://www.science.org/content/article/protein-decoys-viruses-may-battle-covid-19-and-more
OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition of four new industry members: Bayer, Dassault Systèmes, CHARM Therapeutics, and BaseCamp Research Ltd. OpenFold, a consortium of academic and industry partners founded in February 2022, is a […]
Cyrus Scientists Develop Tool for Peptide Design with Non-canonical Amino Acids
https://www.frontiersin.org/articles/10.3389/fmolb.2022.848689/full
‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)
Recently William Haseltine wrote an excellent article on Forbes regarding ACE2 research and the development of therapeutics for SARS-Cov2. The article includes a link to research performed by Cyrus scientists Erik Procko and Kui Chan. If you would like to read the articles, please feel free to follow the links below: ‘Decoy’ Protein Offers New […]
